Q-omics provides the consensus-scored CTU1 profile across patient tissues and cancer cell-line models. CTU1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CTU1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CTU1 RNA expression shows 17,156 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where CTU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTU1 survival associations across molecular data types. CTU1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTU1 RNA expression–survival associations across cancer types. High CTU1 expression shows unfavorable associations in ACC, KIRC, LIHC, CESC and UCS, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CTU1 RNA expression.
This table summarizes CTU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CTU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTU1 shows higher tumor expression in KIRC, COAD, BLCA, HNSC, STAD and LIHC. The KIRC box plot shows higher CTU1 RNA expression in tumor versus normal tissue (log2 FC = +0.552, t-test p < 0.001).
This table shows molecular features associated with CTU1 in patient tissues and cancer cell lines. In patient samples, CTU1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
